Risk Factors of Chronic Kidney Disease in Chronic Hepatitis B: A Hospital-based Case-control Study f

来源 :临床与转化肝病杂志(英文版) | 被引量 : 0次 | 上传用户:huangshjing
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background and Aims: Chronic kidney disease (CKD) usually occurs during the chronic infection of hepatitis B virus (HBV). However, the risk factors of CKD in an HBV population have not been completely demonstrated. Our present study aimed to investigate the risk factors of CKD in chronic HBV infection using a hospital based cross-sec-tional study in the northern area of China. Methods: Dur-ing January 2013 to December 2017, a total of 94 patients with CKD complicated by chronic HBV infection were con-secutively enrolled in the study, as well as 548 age- and sex-matched hepatitis B patients without CKD who were enrolled as controls. Univariate and multivariate regression analyses were used to determine the effects of each vari-able after adjusting for cofounding factors. Results: Mul-tivariate analysis showed that HBeAg-positive status (odds ratio [OR]=2.099, 95% CI 1.128–3.907), dyslipidemia (OR: 3.025, 95% CI 1.747–5.239), and hypertension (OR: 12.523, 95% CI 6.283–24.958) were independently associ-ated with the incidence of CKD, while duration of HBV in-fection (≥240 months) (OR: 0.401, 95% CI 0.179–0.894), Log10 HBsAg (OR: 0.514, 95% CI 0.336–0.786), and coro-nary heart disease (OR: 0.078, 95% CI 0.008–0.768) were protective factors for the incidence of CKD. Duration of HBV infection, Log10 HBsAg, HBeAg-positive status and dyslipi-demia remained the risk factors for CKD after adjusting for diabetes mellitus, hypertension, and coronary heart dis-ease. Conclusions: Duration of HBV infection, Log10 HB-sAg, HBeAg-positive status and dyslipidemia contributed to the incidence of CKD during chronic HBV infection in a Chinese population.
其他文献
目的:基于名老中医睾丸炎辨治医案,通过文本挖掘和数据清洗进行集内关联挖掘,形成医案解析,从中分析研究名老中医治疗睾丸炎的经验.方法:采用优化数据的集内关联挖掘方法,进行医案解构分析.结果:本次研究涉及患者92人次,病例200诊次,症状118种,脉象12种,舌象25种,病机11条,药物184味.经集内关联处理,产生核心规则症状25组;舌象18组;脉象21组;药物23组,治法29组.结论:中医名医辨治睾丸炎时,临床高关联症状为“阴囊肿胀”“阴囊疼痛”“阴囊灼热”“阴囊色红”“发热”等,临床高关联舌象为“苔黄”
目的:观察病情处于缓解期的哮喘病患儿接受补脾益肺推拿手法治疗的临床效果.方法:选取2021年2月-2021年10月在我院进行治疗的76例病情处于缓解期阶段的哮喘病患儿,根据治疗方法的差异分为对照组和治疗组,各38例.对照组接受常规小儿哮喘治疗干预,治疗组在常规小儿哮喘治疗干预方案基础上,增加实施补脾益肺推拿手法治疗.对比两组在治疗前后呼出一氧化氮水平、不良反应、哮喘症状消失、病情控制总有效率.结果:治疗组在治疗前后呼出一氧化氮水平的改善幅度大于对照组,组间比较差异有统计学意义(P<0.05);不良反应少于
目的:探讨依达拉奉联合银杏二萜内酯治疗脑梗死后功能障碍的效果.方法:选取2019年1月-2021年5月于我院收治的90例脑梗死后功能障碍患者作为研究对象,通过随机数表法分为研究组和对照组,各45例,两组均行基础治疗,对照组在基础治疗上增加银杏二萜内酯进行治疗,研究组于对照组基础上增加依达拉奉进行治疗,对比两组炎症指标、血液指标及神经功能.结果:研究组治疗后血清肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、超敏C反应蛋白(hs-CRP)低于对照组(P<0.05);研究组治疗后红细胞比容(HCT)、血浆
目的 研究基于“3H”理论的全程优质护理在内镜下介入术治疗食管胃底静脉曲张患者中的应用效果.方法 选取我院2017年1月至2021年1月收治的58例食管胃底静脉曲张患者,采用随机数字表法将其分为对照组和观察组,各29例.对照组开展围术期常规护理干预,观察组在对照组基础上开展基于“3H”理论的全程优质护理干预.比较两组的干预效果.结果 观察组的出血量少于对照组,出血停止时间及住院时间均短于对照组(P<0.05).观察组的并发症总发生率为6.90%,低于对照组的27.59%(P<0.05).干预后,两组的各维
Omics data address key issues in liver transplantation (LT) as the most effective therapeutic means for end-stage liver dis-ease. The purpose of this study was to review the current ap-plication and future direction for omics in LT. We reviewed the use of
[背景]噪声对机体产生多种负面影响,肠道菌群受环境影响并与疾病的发生密切相关.目前关于长期噪声暴露对肠道菌群的影响知之甚少.[目的]研究旨在探究噪声暴露对大鼠肠道菌群结构的影响,并进行菌群功能预测.[方法]雄性Wistar大鼠(6周龄,160~180 g)被随机分为对照、95 dB噪声暴露(NE_95dB)组和105 dB噪声暴露(NE_105dB)组,每组10只.NE_95dB和NE_105dB组大鼠分别暴露于95 dB声压级(SPL)及105 dB SPL的噪声中,每天4 h,连续30 d,对照组则暴
Background and Aims: Vibration-controlled transient elastography (VCTE) is a noninvasive tool that uses liv-er stiffness measurement (LSM) to assess fibrosis. Since real-life data during everyday clinical practice in the USA are lacking, we describe the p
Background and Aims: We compared lung function parameters in nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD), and examined the association between lung function parameters and fibrosis severity in
Background and Aims: Previous studies have reported that the single nucleotide polymorphisms (SNPs) of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 are associated with nonalcoholic fatty liver disease (NAFLD). However, no studies have examined the
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects a third of the population and is a leading cause of liver-related death. Since no effective treatments exist, novel approaches to drug development are required. Unfortunately, outdated